Logo-ipp

Immunopathol Persa. 2021;7(2): e12. doi: 10.34172/ipp.2021.12

Editorial

Controversy with bromhexine in COVID-19; where we stand

Ramin Tolouian 1 * ORCID, Zuber D. Mulla 2 ORCID

Cited by CrossRef: 3

1- Mitev V, Mondeshki T, Miteva A, Tachkov K, Dimitrova V. COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride. Immunity Inflam & Disease. 2026;14(4) [Crossref]
2- Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib. PHAR. 2023;70(4):1177 [Crossref]
3- Mondeshki T, Bilyukov R, Tomov T, Mihaylov M, Mitev V. Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations With Bromhexine, Higher Doses of Colchicine, and Hymecromone. 2022; [Crossref]